Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Korro Bio today and set a price target of $180.00. The company’s shares closed yesterday at $45.72.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Rahimi is a 5-star analyst with an average return of 13.1% and a 41.74% success rate. Rahimi covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Soleno Therapeutics, and Crinetics Pharmaceuticals.
Korro Bio has an analyst consensus of Strong Buy, with a price target consensus of $125.50, implying a 174.50% upside from current levels. In a report released on September 16, BMO Capital also maintained a Buy rating on the stock with a $80.00 price target.
KRRO market cap is currently $412.3M and has a P/E ratio of -4.69.
Read More on KRRO:
Disclaimer & DisclosureReport an Issue
- Korro Bio management to meet with Piper Sandler
- Korro Bio’s Promising RNA Editing Advances and Market Potential Highlighted by Buy Rating
- Korro Bio’s KRRO-110: Promising Safety, Efficacy, and Commercial Potential Drive Buy Rating
- Korro Bio price target lowered to $90 from $100 at H.C. Wainwright
- Korro Bio Advances RNA Editing Programs in Q2 2025
/Microsoft%20Corporation%20logo%20on%20sign-by%20Jean-Luc%20Ichard%20via%20iStock.jpg)
/ServiceNow%20Inc%20logo%20on%20phone-by%20rafapress%20via%20Shutterstock.jpg)